Top Story

Evolving primary cancer treatments spur changes in secondary APL rates

April 17, 2015

Changes to the treatment of primary tumors are associated with increased rates of secondary acute promyelocytic leukemia among patients with prostate cancer but decreased rates among patients with breast cancer, according to study results.

Characteristics and outcomes were similar among patients with secondary or de novo acute promyelocytic leukemia (APL), results also showed.

In the Journals

Lower intensity treatment regimen displays efficacy in older patients with AML

April 16, 2015
Treatment with clofarabine and low-dose cytarabine alternating with decitabine was well tolerated and highly effective in older patients with acute myeloid leukemia…
Heiko Schöder, MD In the Journals

Surveillance imaging unnecessary for most patients with early-stage Hodgkin's lymphoma

April 15, 2015
Routine radiologic surveillance with CT or PET/CT can be safely omitted for patients with early-stage Hodgkin’s lymphoma who are treated with a specific…
In the Journals

Expert panel agrees BIA-ALCL is less aggressive biologically, has good prognosis

April 13, 2015
After a review of the published literature, a multidisciplinary panel of 12 experts published their findings and assessment of a number of incompletely addressed issues…
CME CNE
Low Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
Meeting News Coverage Video
Genome editing demonstrated wide application for blood disorders

Genome editing demonstrated wide application for blood disorders

January 4, 2015
SAN FRANCISCO — Ralph Green, MD, PhD, FRCPath, medical director of the UC Davis Health System Medical…
More »
CME
Hematology Oncology Case Consults

Diagnosis and Management of Hemophilia

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of the patient with hemophilia supplemented with a case…
More »
In the Journals

Evolving primary cancer treatments spur changes in secondary APL rates

April 17, 2015
Changes to the treatment of primary tumors are associated with increased rates of secondary acute promyelocytic leukemia among patients with prostate…
In the Journals

Lower intensity treatment regimen displays efficacy in older patients with AML

April 16, 2015
Treatment with clofarabine and low-dose cytarabine alternating with decitabine was well tolerated and highly effective in older patients with acute…
Heiko Schöder, MD In the Journals

Surveillance imaging unnecessary for most patients with early-stage Hodgkin's lymphoma

April 15, 2015
Routine radiologic surveillance with CT or PET/CT can be safely omitted for patients with early-stage Hodgkin’s lymphoma who are treated with a…
In the Journals

Expert panel agrees BIA-ALCL is less aggressive biologically, has good prognosis

April 13, 2015
After a review of the published literature, a multidisciplinary panel of 12 experts published their findings and assessment of a number of…
In the Journals

MRD monitoring may guide risk-based therapy in pediatric ALL

April 10, 2015
The sequential monitoring of minimal residual disease levels during remission induction in pediatric patients with acute lymphoblastic leukemia may…
Cure rates for patients with Hodgkin’s lymphoma range between 75% and 80%. Cover StoryPublication Exclusive

Targeted agents trigger ‘paradigm shift’ in treatment of Hodgkin’s lymphoma

HemOnc Today, April 10, 2015
The success of targeted drugs and immunotherapies has triggered a seismic shift in cancer treatment.As the potential increases for these personalized…
 Steven P. Treon, MD, PhD In the Journals

Ibrutinib safe, effective in previously treated Waldenström’s macroglobulinemia

April 8, 2015
Treatment with ibrutinib yielded durable responses and proved safe in patients with previously treated Waldenström’s macroglobulinemia…
In the Journals

Pacritinib demonstrates safety, efficacy for patients with myelofibrosis

April 7, 2015
Pacritinib safely improved disease-related symptoms and reduced spleen volume in patients with myelofibrosis who had pre-existing anemia and…
FDA News

FDA grants orphan drug designation to CUDC-907 for DLBCL

April 6, 2015
The FDA today granted orphan drug designation to CUDC-907 for the treatment of diffuse large B-cell lymphoma, according to a press release from the…
In the Journals

HSCT outcomes similar in pediatric ALL regardless of donor type

April 6, 2015
 Pediatric patients with high-risk acute lymphoblastic leukemia who underwent hematopoietic stem cell transplantation with matched unrelated…
More Headlines »
morganatic-roan
morganatic-roan